openFDA
Cure8 regulatory brief
Why This Matters
This is the official FDA drug label for dexamethasone sodium phosphate. It names ulcerative colitis and regional enteritis (Crohn’s disease) among indications where systemic corticosteroids can be used, so it’s relevant for IBD patients and their clinicians considering steroid therapy for acute control.
Who Should Pay Attention
Adult patients with IBD (ulcerative colitis or Crohn’s disease), clinicians who prescribe corticosteroids, and caregivers involved in acute IBD management.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
This update documents the official prescribing information for dexamethasone sodium phosphate, a corticosteroid formulation used in many acute and chronic inflammatory conditions.
For people with IBD, the label explicitly lists ulcerative colitis and regional enteritis as indications where systemic corticosteroid therapy may be used to "tide the patient over a critical period." The label describes intravenous and intramuscular routes and provides general dosing ranges and administration notes (including dilution and neonatal precautions).
If you take or might be prescribed this medicine, the label is intended for clinicians and includes clinical details (indications, dosing ranges, routes, and safety considerations) that your prescribing provider will use to guide treatment decisions.
This document is the regulatory drug label rather than a treatment guideline; it does not replace individualized medical advice.
Keep In Mind
This is a regulatory drug-label record (prescribing information). Labels describe approved uses, dosing options, administration routes, and safety details but are not clinical practice guidelines. Treatment decisions (when to use steroids, doses, and duration) should be individualized by a clinician.
The label lists many indications beyond IBD and includes specific administration cautions (e.g., neonatal preservative guidance).
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
PublisherU.S. Food and Drug Administration
SponsorSportpharm LLC
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedAug 31, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Dexamethasone FDA label update (2026-07-17)
The FDA label for dexamethasone explicitly lists regional enteritis (Crohn's disease) and ulcerative colitis among its gastrointestinal indications, and provides dosing guidance and steroid-equivalent tables that are...
PredniSONE FDA label update (2026-07-10)
Prednisone is a commonly used steroid for short-term control of IBD flares; changes or reaffirmations in its FDA label affect prescribing and safety guidance that patients and clinicians rely on.
METHYLPREDNISOLONE SODIUM SUCCINATE FDA label update (2026-07-24)
This label update details how injectable methylprednisolone can be used in acute/critical situations for inflammatory bowel diseases (regional enteritis/Crohn’s disease and ulcerative colitis), including dosing and...